Austar Lifesciences (HKG:6118) logged a profit attributable to owners of 25 million yuan for the first half of 2025, up from 5.88 million yuan a year earlier, according to a Tuesday Hong Kong bourse filing.
Earnings per share came in at 0.05 yuan, compared with 0.01 yuan in the prior-year period.
Revenue slipped to 661.9 million yuan from 700.9 million yuan.
The board declared no dividend.